MarketPulse
T

$TNGX

3 articles found
2 positive
0 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Equity-Insider.Com

Patent Cliff Accelerates Biotech Rotation: Five Precision Oncology Firms Poised for Breakthrough

Institutional investors rotate capital to precision oncology biotech as patent cliff pressures Big Pharma. Five clinical-stage companies positioned for M&A amid $303B market opportunity.
SNSEONCYTNGXOSTXATOSFDA approvalbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Tango Therapeutics Awards Stock Options, RSUs to New Executive Under Nasdaq Rules

Tango Therapeutics grants new employee 367,500 stock options and 60,000 RSUs valued at $11.94 exercise price under inducement plan.
TNGXrestricted stock unitsvesting schedule
The Motley FoolThe Motley Fool··Jake Lerch

Boxer Capital Doubles Down on TNGX With $9.5M Stake as Biotech Stock Soars

Boxer Capital invests $9.5M in clinical-stage biotech $TNGX, raising stake to 21.09%, as stock surges 427% amid Gilead partnership momentum.
GILDTNGXIBBbiotechclinical-stage